HRTX
Heron Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.34
+4.21%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.2x
Market Cap
$65.29M
MomentumView details →
1D Return
+4.21%
YTD Return
−73.70%
RSI (14)
44.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.2x
Market Cap
$65.29M
RSI (14)
44.2
MomentumView details →
1D Return
+4.21%
YTD Return
−73.70%
SummaryUpdated Jun 1, 2026
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a San Diego-based biotechnology company founded in 1983 that develops specialized treatments for unmet medical needs in oncology and acute care settings. Originally known as A.P. Pharma, Inc., the company rebranded to Heron Therapeutics in 2014 to reflect its focus on innovative drug delivery technologies. The company has evolved from a development-stage biotechnology firm to a commercial-stage pharmaceutical company with multiple approved products generating over $144 million in annual revenue as of 2024.
Similar companies
Latest newsMore news →
Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.26d agoThe U.S. District Court for the District of Delaware issued a decision in patent litigation between Heron Therapeutics and Azurity Pharmaceuticals, holding Heron's asserted patents for CINVANTI invalid.94d ago